BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 23432690)

  • 1. Decreased 5-hydroxymethylcytosine levels are associated with TET2 mutation and unfavorable overall survival in myelodysplastic syndromes.
    Liu X; Zhang G; Yi Y; Xiao L; Pei M; Liu S; Luo Y; Zhong H; Xu Y; Zheng W; Shen J
    Leuk Lymphoma; 2013 Nov; 54(11):2466-73. PubMed ID: 23432690
    [TBL] [Abstract][Full Text] [Related]  

  • 2. TET2 expression level and 5-hydroxymethylcytosine are decreased in refractory cytopenia of childhood.
    Coutinho DF; Monte-Mór BC; Vianna DT; Rouxinol ST; Batalha AB; Bueno AP; Boulhosa AM; Fernandez TS; Pombo-de-Oliveira MS; Gutiyama LM; Abdelhay E; Zalcberg IR
    Leuk Res; 2015 Oct; 39(10):1103-8. PubMed ID: 26277372
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Alterations of the expression of TET2 and DNA 5-hmC predict poor prognosis in Myelodysplastic Neoplasms.
    Seethy AA; Pethusamy K; Kushwaha T; Kumar G; Talukdar J; Chaubey R; Sundaram UD; Mahapatra M; Saxena R; Dhar R; Inampudi KK; Karmakar S
    BMC Cancer; 2023 Oct; 23(1):1035. PubMed ID: 37884893
    [TBL] [Abstract][Full Text] [Related]  

  • 4. TET2 mutations as a part of DNA dioxygenase deficiency in myelodysplastic syndromes.
    Gurnari C; Pagliuca S; Guan Y; Adema V; Hershberger CE; Ni Y; Awada H; Kongkiatkamon S; Zawit M; Coutinho DF; Zalcberg IR; Ahn JS; Kim HJ; Kim DDH; Minden MD; Jansen JH; Meggendorfer M; Haferlach C; Jha BK; Haferlach T; Maciejewski JP; Visconte V
    Blood Adv; 2022 Jan; 6(1):100-107. PubMed ID: 34768283
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic significance of TET2 mutations in myelodysplastic syndromes: A meta-analysis.
    Guo Z; Zhang SK; Zou Z; Fan RH; Lyu XD
    Leuk Res; 2017 Jul; 58():102-107. PubMed ID: 28521175
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impaired hydroxylation of 5-methylcytosine in myeloid cancers with mutant TET2.
    Ko M; Huang Y; Jankowska AM; Pape UJ; Tahiliani M; Bandukwala HS; An J; Lamperti ED; Koh KP; Ganetzky R; Liu XS; Aravind L; Agarwal S; Maciejewski JP; Rao A
    Nature; 2010 Dec; 468(7325):839-43. PubMed ID: 21057493
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Low Ten-eleven-translocation 2 (TET2) transcript level is independent of TET2 mutation in patients with myeloid neoplasms.
    Scopim-Ribeiro R; Machado-Neto JA; de Melo Campos P; Niemann FS; Lorand-Metze I; Costa FF; Olalla Saad ST; Traina F
    Diagn Pathol; 2016 Mar; 11():28. PubMed ID: 26984174
    [TBL] [Abstract][Full Text] [Related]  

  • 8. TET2 Mutation and High miR-22 Expression as Biomarkers to Predict Clinical Outcome in Myelodysplastic Syndrome Patients Treated with Hypomethylating Therapy.
    Yun J; Ji YS; Jang GH; Lim SH; Kim SH; Kim CK; Bae SB; Won JH; Park SK
    Curr Issues Mol Biol; 2021 Aug; 43(2):917-931. PubMed ID: 34449560
    [TBL] [Abstract][Full Text] [Related]  

  • 9. TET2 mutation is an independent favorable prognostic factor in myelodysplastic syndromes (MDSs).
    Kosmider O; Gelsi-Boyer V; Cheok M; Grabar S; Della-Valle V; Picard F; Viguié F; Quesnel B; Beyne-Rauzy O; Solary E; Vey N; Hunault-Berger M; Fenaux P; Mansat-De Mas V; Delabesse E; Guardiola P; Lacombe C; Vainchenker W; Preudhomme C; Dreyfus F; Bernard OA; Birnbaum D; Fontenay M;
    Blood; 2009 Oct; 114(15):3285-91. PubMed ID: 19666869
    [TBL] [Abstract][Full Text] [Related]  

  • 10. TET family proteins and 5-hydroxymethylcytosine in esophageal squamous cell carcinoma.
    Murata A; Baba Y; Ishimoto T; Miyake K; Kosumi K; Harada K; Kurashige J; Iwagami S; Sakamoto Y; Miyamoto Y; Yoshida N; Yamamoto M; Oda S; Watanabe M; Nakao M; Baba H
    Oncotarget; 2015 Sep; 6(27):23372-82. PubMed ID: 26093090
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Next-generation sequencing of the TET2 gene in 355 MDS and CMML patients reveals low-abundance mutant clones with early origins, but indicates no definite prognostic value.
    Smith AE; Mohamedali AM; Kulasekararaj A; Lim Z; Gäken J; Lea NC; Przychodzen B; Mian SA; Nasser EE; Shooter C; Westwood NB; Strupp C; Gattermann N; Maciejewski JP; Germing U; Mufti GJ
    Blood; 2010 Nov; 116(19):3923-32. PubMed ID: 20693430
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reduction of global 5-hydroxymethylcytosine is a poor prognostic factor in breast cancer patients, especially for an ER/PR-negative subtype.
    Tsai KW; Li GC; Chen CH; Yeh MH; Huang JS; Tseng HH; Fu TY; Liou HH; Pan HW; Huang SF; Chen CC; Chang HY; Ger LP; Chang HT
    Breast Cancer Res Treat; 2015 Aug; 153(1):219-34. PubMed ID: 26253945
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ten-eleven-translocation 2 (TET2) is downregulated in myelodysplastic syndromes.
    Scopim-Ribeiro R; Machado-Neto JA; Campos Pde M; Silva CA; Favaro P; Lorand-Metze I; Costa FF; Saad ST; Traina F
    Eur J Haematol; 2015 May; 94(5):413-8. PubMed ID: 25200248
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Down-regulation of TET2 in CD3⁺ and CD34⁺ cells of myelodysplastic syndromes and enhances CD34⁺ cells proliferation.
    Zhang W; Shao Z; Fu R; Wang H; Li L; Liu H
    Int J Clin Exp Pathol; 2015; 8(9):10840-6. PubMed ID: 26617797
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibition of TET2-mediated conversion of 5-methylcytosine to 5-hydroxymethylcytosine disturbs erythroid and granulomonocytic differentiation of human hematopoietic progenitors.
    Pronier E; Almire C; Mokrani H; Vasanthakumar A; Simon A; da Costa Reis Monte Mor B; Massé A; Le Couédic JP; Pendino F; Carbonne B; Larghero J; Ravanat JL; Casadevall N; Bernard OA; Droin N; Solary E; Godley LA; Vainchenker W; Plo I; Delhommeau F
    Blood; 2011 Sep; 118(9):2551-5. PubMed ID: 21734233
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The lower risk MDS patient at risk of rapid progression.
    Mittelman M; Oster HS; Hoffman M; Neumann D
    Leuk Res; 2010 Dec; 34(12):1551-5. PubMed ID: 20573398
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic role of TET2 deficiency in myelodysplastic syndromes: A meta-analysis.
    Lin Y; Lin Z; Cheng K; Fang Z; Li Z; Luo Y; Xu B
    Oncotarget; 2017 Jun; 8(26):43295-43305. PubMed ID: 28476038
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of TET2 mutations on response rate to azacitidine in myelodysplastic syndromes and low blast count acute myeloid leukemias.
    Itzykson R; Kosmider O; Cluzeau T; Mansat-De Mas V; Dreyfus F; Beyne-Rauzy O; Quesnel B; Vey N; Gelsi-Boyer V; Raynaud S; Preudhomme C; Adès L; Fenaux P; Fontenay M;
    Leukemia; 2011 Jul; 25(7):1147-52. PubMed ID: 21494260
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A novel scoring system integrating molecular abnormalities with IPSS-R can improve the risk stratification in patients with MDS.
    Gu S; Xia J; Tian Y; Zi J; Ge Z
    BMC Cancer; 2021 Feb; 21(1):134. PubMed ID: 33549060
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [An update on epigenetic regulator gene mutations and pathogenesis of myelodysplastic syndromes].
    Wang JY; Xiao ZJ
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2011 Oct; 19(5):1303-9. PubMed ID: 22040993
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.